|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schöppner P, Csaba G, Braun T, Daake M,
Richter B, Lange OF, Zacharias M, Zimmer R and Haslbeck M:
Regulatory implications of non-trivial splicing: isoform 3 of Rab1A
shows enhanced basal activity and is not controlled by accessory
proteins. J Mol Biol. 428:1544–1557. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Allan BB, Moyer BD and Balch WE: Rab1
recruitment of p115 into a cis-SNARE complex: programming budding
COPII vesicles for fusion. Science. 289:444–448. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Satoh A, Wang Y, Malsam J, Beard MB and
Warren G: Golgin-84 is a rab1 binding partner involved in Golgi
structure. Traffic. 4:153–161. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Coune PG, Bensadoun JC, Aebischer P and
Schneider BL: Rab1A over-expression prevents Golgi apparatus
fragmentation and partially corrects motor deficits in an
alpha-synuclein based rat model of Parkinson's disease. J
Parkinsons Dis. 1:373–387. 2011.PubMed/NCBI
|
|
8
|
Park JS, Heo JS, Chang HS, Choi IS, Kim
MK, Lee JU, Park BL, Shin HD and Park CS: Association analysis of
member RAS oncogene family gene polymorphisms with aspirin
intolerance in asthmatic patients. DNA Cell Biol. 33:155–161. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu G, Yussman MG, Barrett TJ, Hahn HS,
Osinska H, Hilliard GM, Wang X, Toyokawa T, Yatani A, Lynch RA, et
al: Increased myocardial Rab GTPase expression: a consequence and
cause of cardiomyopathy. Circ Res. 89:1130–1137. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimada K, Uzawa K, Kato M, Endo Y, Shiiba
M, Bukawa H, Yokoe H, Seki N and Tanzawa H: Aberrant expression of
RAB1A in human tongue cancer. Br J Cancer. 92:1915–1921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang Y, Hou N, Wang X, Wang L, Chang S, He
K, Zhao Z, Zhao X, Song T and Huang C: miR-15b-5p induces
endoplasmic reticulum stress and apoptosis in human hepatocellular
carcinoma, both in vitro and in vivo, by suppressing Rab1A.
Oncotarget. 6:16227–16238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Chu Y, Wang W and Yuan W: mTORC
signaling in hematopoiesis. Int J Hematol. 103:510–518. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thomas JD, Zhang YJ, Wei YH, Cho JH,
Morris LE, Wang HY and Zheng XF: Rab1A is an mTORC1 activator and a
colorectal oncogene. Cancer Cell. 26:754–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun T, Wang X, He HH, Sweeney CJ, Liu SX,
Brown M, Balk S, Lee GS and Kantoff PW: miR-221 promotes the
development of androgen independence in prostate cancer cells via
downregulation of HECTD2 and RAB1A. Oncogene. 33:2790–2800. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu BH, Li XX, Yang Y, Zhang MY, Rao HL,
Wang HY and Zheng XF: Aberrant amino acid signaling promotes growth
and metastasis of hepatocellular carcinomas through Rab1A-dependent
activation of mTORC1 by Rab1A. Oncotarget. 6:20813–20828. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gulhati P, Bowen KA, Liu J, Stevens PD,
Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T, et al:
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of
colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res.
71:3246–3256. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Makki J, Myint O, Wynn AA, Samsudin AT and
John DV: Expression distribution of cancer stem cells, epithelial
to mesenchymal transition, and telomerase activity in breast cancer
and their association with clinicopathologic characteristics. Clin
Med Insights Pathol. 8:1–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng K, Zhou X, Yu J, Li Q, Wang H, Li M,
Shao Z, Zhang F, Luo Y, Shen Z, et al: Epigenetic silencing of
miR-490-3p promotes development of an aggressive colorectal cancer
phenotype through activation of the Wnt/β-catenin signaling
pathway. Cancer Lett. 376:178–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu Q, Wang J, Yu G, Guo T, Hu C and Ren P:
Expression and clinical significance of mammalian target of
rapamycin/P70 ribosomal protein S6 kinase signaling pathway in
human colorectal carcinoma tissue. Oncol Lett. 10:277–282.
2015.PubMed/NCBI
|
